Soluble Urokinase Plasminogen Activator Receptor in Preoperatively Obtained Plasma from Patients with Gynecological Cancer or Benign Gynecological Diseases

By Riisbro R.   Stephens R.W.   Brunner N.   Christensen I.J.   Nielsen H.J.   Heilmann L.   von Tempelhoff G.-F.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 523-531

Elsevier

Access to resources Recommend Favorite

Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

By              

Oncology Letters, Vol. 2, Iss. 4, 2011-01 ,pp. : 693-699

Spandidos Publications

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer

By              

Molecular and Clinical Oncology, Vol. 3, Iss. 6, 2015-01 ,pp. : 1213-1220

Science Publishers

Access to resources Recommend Favorite

Differential mRNA Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor Type-2 in Normal Human Endometria and Endometrial Carcinomas

By Foca C.   Moses E.K.   Quinn M.A.   Rice G.E.  

Gynecologic Oncology, Vol. 79, Iss. 2, 2000-11 ,pp. : 244-250

Elsevier

Access to resources Recommend Favorite